Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by langostaon May 29, 2018 12:35pm
138 Views
Post# 28094128

From the BBC. c'mon TLT we can do better

From the BBC. c'mon TLT we can do better

A vaccine could help to significantly extend the lives of people diagnosed with the brain cancer that killed ex-Labour cabinet minister Tessa Jowell, early trial results suggest.

People with glioblastoma who took part in the study lived more than twice as long as those on standard treatments in many cases, researchers say.

The vaccine works by using the body's immune cells to target the cancer.

A cancer charity said preliminary results seemed "remarkably promising".

The standard treatment for glioblastoma, the most aggressive of brain tumours in adults, involves removing the tumour followed by radiotherapy and chemotherapy.

But it is difficult to treat and patients live on average for only 15 to 17 months after surgery.

For this phase three trial of 331 people from the UK, the US, Canada and Germany, 232 patients were given the immunotherapy vaccine DCVax on top of standard treatments while the rest received a placebo along with normal care.

The vaccine works by taking immune cells, known as dendritic cells, from the patients' bodies and then combining them with a sample of their tumours.

When the vaccine is injected back into the patient, the body's entire immune system recognises the cancer to attack.

Preliminary results from the 11-year study, published in the Journal of Translational Medicine, found those involved in the trial survived for more than 23 months on average after surgery, with 100 living for 40.5 months at the time of the researchers' analysis.

Because the study has not concluded yet, the data does not break down who received the vaccine and who had the placebo, but this will be released when the trial concludes.

The longest survivors have lived for more than seven years after surgery.

The study's authors said it appears that patients on the trial who reach a certain threshold beyond diagnosis "may continue onwards to unusually long survival times".


Kat and Jason CharlesImage copyrightBRAIN TUMOUR CHARITY

Vaccine did 'what everyone said was impossible'

Kat Charles was told in 2014 that she had three months to live after NHS doctors ran out of options to treat her brain cancer.

"They said there was nothing more they could do for me," says Kat, now 36 from Milton Keynes.

"I was distraught."

After undergoing the standard forms of treatment, and even taking part in a clinical trial for another medicine, she and her husband Jason raised funds to pay for DCVax privately.

After receiving the treatment, Kat's most recent MRI scan showed no trace of the tumour.

"DCVax has done what everyone said was impossible," her husband Jason says. "If not for this treatment, I would be without my wife and without a mother for our child."

Kat continues to have regular injections of the vaccine.

"I go to London on the train, I have a shot in each arm and then I'm free to go home. It doesn't give me any side-effects. It's fantastic."

 
Bullboard Posts